ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals (RXHN:OB), a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for cancer and central nervous system disorders, announced today, that its leading oncology candidate, RX-0201 -- now named Archexin -- was included in the March 2007 issue of R&D Directions Magazine’s “100 Great Investigational Drugs.” To be included in the publication’s sixth annual list, compounds in active development had to demonstrate potential in a major or growing therapeutic area, and differentiate themselves as innovative, first-in-class, or advanced, compared to those already on the market.
